

Supplemental Information

miR372 Promotes Progression of Liver

Cancer Cells by Upregulating erbB-2

through Enhancement of YB-1

Zhuojia Lin, Yanan Lu, Qiuyu Meng, Chen Wang, Xiaonan Li, Yuxin Yang, Xiaoru Xin, Qidi Zheng, Jie Xu, Xin Gui, Tianming Li, Hu Pu, Wujun Xiong, Jiao Li, Song Jia, and Dongdong Lu

Supplemental Data

Results


miR372 accelerates growth of liver cancer cells Huh7

We first constructed two stable Huh7 cell lines by infecting with rLV or rLV-miR372. As shown in **FigureS2A**, mature miR372 were significantly overexpressed in rLV- -miR372 group compared to rLV group and Huh7 group respectively. As shown in **FigureS2B**, excessive miR372 significantly increased the growth ability of liver cancer cell Huh7 compared to the rLV group and Huh7 group ($P < 0.01$). And there is no significant difference between rLV group and Huh7 group ($P > 0.05$). Moreover, the BrdU positive rate was significantly increased in rLV-miR372 group compared to rLV group ($61 \pm 7.79\%$ versus $28.23 \pm 4.83\%$, $P = 0.008 < 0.01$) and Huh7 group ($61 \pm 7.79\%$ versus $30.83 \pm 2.83\%$, $P = 0.00743 < 0.01$). However, there is no significant difference between Huh7 group and rLV group ($28.23 \pm 4.83\%$ versus $30.83 \pm 2.83\%$, $P = 0.0779 > 0.05$) (**FigureS2C**). Furthermore, we performed colony formation assay and observed a significant increase in colony formation efficiency rate in rLV-miR372 group compared to rLV group ($65.95 \pm 8.11\%$ versus $41.2 \pm 4.48\%$, $P = 0.0083 < 0.01$) and Huh7 group ($65.95 \pm 8.11\%$ versus $40.3 \pm 2.63\%$, $P = 0.0095 < 0.01$). However, there is no significant difference between Huh7 group and rLV group ($40.3 \pm 2.63\%$ versus $41.2 \pm 4.48\%$, $P = 0.389 > 0.05$) (**FigureS2D**). To further explore the effect of miR372 on liver cancer cells Huh7 in vivo, the two stable Huh7 were injected subcutaneously into athymic Balb/C mice. As shown in FigureS 2Ea, the xenograft tumor weight

was significantly increased in rLV-miR372 group compared to rLV group (1.243 ± 0.278 gram versus 0.68 ± 0.089 gram, $P=0.00353<0.01$) and Huh7 group (1.243 ± 0.278 gram versus 0.637 ± 0.107 , $P=0.00068<0.01$). However, there is no significant difference between Huh7 group and rLV group (0.68 ± 0.089 gram versus 0.637 ± 0.107 gram, $P=0.2089>0.05$). Moreover, PCNA positive rate was significantly increased in rLV- miR372 group compared to rLV group ($65.35\pm 6.94\%$ versus $37.63\pm 5.67\%$, $P=0.00065<0.01$) and Huh7 group ($65.35\pm 6.94\%$ versus $39.55\pm 3.08\%$, $P=0.000012<0.01$). However, there is no significant difference between Huh7 group and rLV group (versus $37.63\pm 5.67\%$, versus $39.55\pm 3.08\%$, $P=0.1506>0.05$) (FigureS2Eb).


Taken together, these findings demonstrate that miR372 accelerates malignant growth of liver cancer cells Huh7.

Figure S1



FigureS1:Cell growth assay *in vitro*.**A.** cells proliferation assay using CCK8 in Hep3B cell and Hep3B cells infected with rLV, respectively. Each value was presented as mean±standard error of the mean (SEM).**B.** cells colony formation ability assay in in Hep3B cell and Hep3B cells infected with rLV, respectively.Each value was presented as mean±standard error of the mean (SEM).


Figure S2



FigureS2:Cell growth assay *in vitro* and *in vivo* in human liver cancer cell Huh7.**A.**The real-time RT-PCR analysis of mature miR372 in human liver cancer cell line Huh7 and Huh7 cells infected with rLV and rLV-miR372, respectively. U6 as internal control.Each value was presented as mean±standard error of the mean (SEM).**B.** cells proliferation assay using CCK8 in human liver cancer cell line Huh7 and Huh7 cells infected with rLV and rLV-miR372, respectively. Each value was presented as mean±standard error of the mean (SEM).**C.** cells BrdU assay.Each value was presented as mean±standard error of the mean (SEM).**D.** cells colony formation ability assay in human liver cancer cell line Huh7 and Huh7 cells infected with rLV and rLV-miR372, respectively.Each value was presented as mean±standard error of the mean (SEM).**E.** Tumorigenesis test *in vivo* .a.The wet weight of each tumor was determined for each mouse. Each value was presented as mean±standard error of


the mean (SEM). **b.**A portion of each tumor was fixed in 4% paraformaldehyde and embedded in paraffin for histological hematoxylin-eosin(HE) staining. Each value was presented as mean±standard error of the mean (SEM).

Figure S3



FigureS3:miR372 influences on the expression of YB-1 and erbB-2in human liver cancer cell Huh7.**A.**The real-time RT-PCR analysis of mature miR372 in human liver cancer cell line Huh7 ,including rLV, rLV-miR372,rLV-miR372 plus pGFP-V-RS-YB-1,and rLV-miR372 plus pGFP-V-RS-erbB-2,respectively. U6 as internal control.Each value was presented as mean±standard error of the mean (SEM).Western blotting with anti-YB-1and anti- erbB-2in human liver cancer cell line Huh7 ,including rLV, rLV-miR372,rLV-miR372 plus pGFP-V-RS-YB-1,and rLV-miR372 plus pGFP-V-RS-erbB-2,respectively.β-actin was used as an internal control.

Figure S4



FigureS4: YB-1 knockdown or erbB-2 knockdown abrogated the functions of miR372 in human liver cancer cell line Huh7. **A.** cells colony formation ability assay in human liver cancer cell line Huh7 , including rLV, rLV-miR372,rLV-miR372 plus pcGFP-V-RS-YB-1, and rLV-miR372 plus pcGFP-V-RS-erbB-2,respectively.Each value was presented as mean±standard error of the mean (SEM).**B.** Tumorigenesis test *in vivo* in human liver cancer cell line Huh7includingrLV, rLV-miR372,rLV-miR372 plus pcGFP-V-RS-YB-1, and rLV-miR372 plus pcGFP-V-RS-erbB-2,respectively. a. The wet weight of each tumor was determined for each mouse. Each value was presented as mean±standard error of the mean (SEM). **b.**A portion of each tumor was fixed in 4% paraformaldehyde and embedded in paraffin for histological hematoxylin-eosin(HE) staining. Each value was presented as mean±standard error of the mean (SEM).